Patents Assigned to Bristol-Myers Squibb Company
  • Publication number: 20240199701
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 24, 2022
    Publication date: June 20, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: JENNIFER X. QIAO, MICHAEL A. POSS, YUNHUI ZHANG, MARTIN PATRICK ALLEN
  • Patent number: 12012452
    Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: June 18, 2024
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
  • Patent number: 12012374
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: June 18, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lalgudi S. Harikrishnan, Muthoni G. Kamau, Brian E. Fink
  • Publication number: 20240190963
    Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a non-small cell lung cancer (NSCLC) comprising administering to the subject a therapeutically effective amount of (a) an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof and (b) an anti-CTLA-4 antibody or an antigen binding portion thereof, wherein the tumor has a high tumor mutation burden (TMB) status. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.
    Type: Application
    Filed: September 15, 2023
    Publication date: June 13, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Prabhu Seshaiyer Bhagavatheeswaran, Nicholas Allan John Botwood, Han Chang, Yali Fu, William J. Geese, George A. Green, IV, Diane Healey, Sabine Maier, Faith E. Nathan, Abderrahim Oukessou, Giovanni Selvaggi, Joseph Daniel Szustakowski
  • Publication number: 20240185972
    Abstract: A method includes receiving input data including unstructured text representing one or more sequences of terms. For each respective sequence of terms, the method includes generating a corresponding line of therapy (LoT) pseudo-label indicating whether the respective sequence of terms includes LoT information, generating a corresponding LoT indicator predicting whether the respective sequence of terms includes LoT information, and determining a corresponding LoT indication loss based on the corresponding LoT pseudo-label and the corresponding LoT indicator. The method also includes fine-tuning a pre-trained transformer model based on the LoT indication losses determined for the one or more sequences of terms.
    Type: Application
    Filed: December 1, 2023
    Publication date: June 6, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Sazedul Alam, Gengyuan Liu, Devansh Agarwal, Md Shamsuzzaman
  • Publication number: 20240180886
    Abstract: Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.
    Type: Application
    Filed: November 8, 2023
    Publication date: June 6, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: YUCHENG MU, HAIBO LIU, ANNAPURNA PENDRI, SHOSHANA L. POSY, JOANNE JEWETT BRONSON, LAURA AKULLIAN D'AGOSTINO
  • Patent number: 11998537
    Abstract: Disclosed are compounds of Formula (I) Formula (I) N-oxides, or salts thereof, wherein G1, G2, L, R1a, R1b, R4, R5, n, m, x, and y are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: June 4, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Brian K. Whiteley, John L. Gilmore
  • Publication number: 20240174749
    Abstract: This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti-TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.
    Type: Application
    Filed: September 27, 2023
    Publication date: May 30, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Guodong CHEN, Michelle Renne KUHNE, Hong-An TRUONG, Poliana PATAH, Jeffrey R. JACKSON, Ronald A. FLEMING
  • Patent number: 11981680
    Abstract: The present invention provides compounds of formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: May 14, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Daniel S. Gardner, John V. Duncia, Joseph B. Santella
  • Patent number: 11981734
    Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: May 14, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Natalie Bezman, Alan J. Korman, Shrikant Deshpande, Amy D. Jhatakia, Richard Y. Huang, Guodong Chen, Ginger C. Rakestraw, Karla Ann Henning, Vangipuram S. Rangan, Christine Bee, Xiang Shao
  • Patent number: 11970511
    Abstract: The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: April 30, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Li Xu, David S. Yoon, Alicia Regueiro-Ren, Prasada Rao Jalagam, Manoranjan Panda, Satheesh Kesavan Nair
  • Publication number: 20240132622
    Abstract: The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.
    Type: Application
    Filed: July 20, 2023
    Publication date: April 25, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Lin Hui Su, Ekaterina Deyanova, Burce Ergel Gurbuzbalaban, Mariana Nacht, Samantha Elaine Pace, Yun Wang, Qing Xiao, Ramakrishna Chandran, Shailesh Dudhgaonkar, Michael Louis Doyle, Michael Gilman, Richard Huang, Akbar Nayeem, Alok Sharma, Qihong Zhao
  • Patent number: 11964973
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR6 or N; Y is CR3 or N; R1, R2, R3, R4, R5, R6, R7, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: April 23, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert G. Gentles, Upender Velaparthi, Min Ding, Richard E. Olson, Scott W. Martin, Saumya Roy, Prasada Rao Jalagam, Jayakumar Sankara Warrier, Louis S. Chupak, Denise Christine Grunenfelder
  • Patent number: 11965031
    Abstract: This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: April 23, 2024
    Assignees: Bristol-Myers Squibb Company, Celldex Therapeutics, Inc.
    Inventors: Vladimir Coric, Tibor Keler, Thomas Davis
  • Publication number: 20240124589
    Abstract: This disclosure provides a method for treating a subject afflicted with a urothelial carcinoma or cancer derived therefrom, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
    Type: Application
    Filed: September 25, 2023
    Publication date: April 18, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventor: Marina TSCHAIKA
  • Publication number: 20240124597
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: August 22, 2023
    Publication date: April 18, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
  • Publication number: 20240124592
    Abstract: This disclosure provides a method for treating HPV-positive squamous cell carcinoma of the head and neck comprising administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The disclosure also provides a method for treating HPV-negative squamous cell carcinoma of the head and neck administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The subject can be additionally administered another anti-cancer agent.
    Type: Application
    Filed: July 26, 2023
    Publication date: April 18, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Demetrios MANEKAS, Joseph GROSSO, Jeffrey A. ANDERSON
  • Publication number: 20240124417
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: October 1, 2020
    Publication date: April 18, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kap-Sun YEUNG, Denis R. ST. LAURENT, Li-Qiang SUN, Zhiwei YIN, Katharine A. GRANT-YOUNG, Paul Michael SCOLA
  • Publication number: 20240127451
    Abstract: Described herein are methods and computer systems for classification of CD8 T-cell topology using a patient response-based linear cutoff model. A plurality of histology images of tissue samples in a plurality of patients are received by a computer system. An image analysis of the plurality of histology images is performed to obtain a CD8+ T-cell abundance in the tumor parenchyma and stroma in each of the plurality of histology images. Real inflammation scores and tumor infiltration scores are determined based on a polar coordinate transformation of the CD8+ T-cell abundance in the tumor parenchyma and stroma. Based on the real inflammation scores and tumor infiltration scores, a feature space is generated, and linear boundaries or linear cutoffs between a plurality of classifications in the feature space are identified based on the real inflammation scores, the tumor infiltration scores, and patient response data.
    Type: Application
    Filed: February 25, 2022
    Publication date: April 18, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: George C. Lee, Robin Edwards, Scott Ely, Daniel N. Cohen, John B. Wojcik, Vipul A. Baxi, Dimple Pandya, Jimena Trillo-Tinoco, Benjamin J. Chen, Andrew Fisher, Falon Gray
  • Patent number: RE49931
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: April 23, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar